Tetrac
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities[1][2].
Product Specifications
CAS Number
67-30-1
Product Name Alternative
Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid
UNSPSC
12352005
Hazard Statement
H300
Target
Endogenous Metabolite; Integrin
Related Pathways
Cytoskeleton; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Concentration
10mM
Purity
99.21
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1
Molecular Formula
C14H8I4O4
Molecular Weight
747.83
Precautions
H300
References & Citations
[1]Schmohl KA, et, al. Tetrac as an anti-angiogenic agent in cancer. Endocr Relat Cancer. 2019 Jun 1; 26 (6) :R287-R304.|[2]Davis PJ, et, al. Nongenomic Actions of Thyroid Hormone: the Integrin Component. Physiol Rev. 2020 Jun 25.|[3]Chin YT, et, al. Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status. Front Endocrinol (Lausanne) . 2019 Mar 12; 10:130.|[4]Ashur-Fabian O, et, al. Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. Front Endocrinol (Lausanne) . 2019 Jan 8; 9:775.|[5]Rajabi M, et, al. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer. Bioorg Med Chem Lett. 2018 Apr 15;28 (7) :1223-1227.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB2603-100 1x 100 µL
Calretinin / Calbindin 2 (Mesothelioma Marker) (CALB2/2603), 0.2mg/mL
Sign In for Pricing
View Details 
